Scinai Immunotherapeutics (SCNI) Operating Leases (2019 - 2026)
Scinai Immunotherapeutics (SCNI) posted Operating Leases of $2.9 million for Q1 2026, up 73.66% sequentially from $1.6 million in Q4 2025.
Scinai Immunotherapeutics (SCNI) Operating Leases (2019 - 2026) Analysis & Trends
Scinai Immunotherapeutics has reported Operating Leases for 8 years, with the latest figure at $2.9 million in Q1 2026.
- Quarterly Operating Leases changed N/A year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (changed N/A YoY) and the FY2025 annual result came in at $1.6 million, up 17.26% from the prior year.
- Operating Leases improved to $2.9 million in Q1 2026 per SCNI's latest filing, from $1.6 million in the prior quarter.
- Over five years, Operating Leases peaked at $2.9 million in Q1 2026 and troughed at $343000.0 in Q4 2023.
- A 5-year average of $1.1 million and a median of $927000.0 in 2023 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2024: Operating Leases plunged 75.73% in 2022, then jumped 308.75% in 2024.
- Over 5 years, Operating Leases stood at $351000.0 in 2022, then dropped by 2.28% to $343000.0 in 2023, then soared by 308.75% to $1.4 million in 2024, then advanced by 17.26% to $1.6 million in 2025, then surged by 73.66% to $2.9 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $2.9 million, $1.6 million, and $1.6 million for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - |
| 10 | Scinai Immunotherapeutics | 12.19 Mn | -3.10 Bn | -1.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.86 Mn |
| Dec 31, 2025 | 1.64 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | 583,000.00 |
| Jun 30, 2024 | 640,000.00 |
| Mar 31, 2024 | 732,000.00 |
| Dec 31, 2023 | 343,000.00 |
| Sep 30, 2023 | 823,000.00 |
| Jun 30, 2023 | 927,000.00 |
| Mar 31, 2023 | 1.01 Mn |
| Dec 31, 2022 | 351,000.00 |
| Jun 30, 2022 | 1.58 Mn |
| Dec 31, 2021 | 1.45 Mn |
| Sep 30, 2021 | 1.83 Mn |
| Dec 31, 2020 | 1.89 Mn |
| Sep 30, 2020 | 1.82 Mn |
| Jun 30, 2020 | 1.86 Mn |
| Dec 31, 2019 | 1.97 Mn |
| Sep 30, 2019 | 1.98 Mn |